Travere Therapeutics
Last updated Jul 26, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
74%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Nephrology
- Drug
- SGLT2 Inhibitor
Highest priority development: CDER Nitrosamine Impurity Acceptable Intake Limits
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Travere Therapeutics; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 74%
Active Signals
2
Investigate Priority
0
Opportunity Score
47
Buyer Quality
8 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 26, 2026Score 27FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)
Nephrology · Drug
- MonitorJun 10, 2026Score 20FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
Nephrology · SGLT2 Inhibitor
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- CDER Nitrosamine Impurity Acceptable Intake LimitsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver InjuryModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — FILSPARI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - GDUFA III Controlled Correspondence EnhancementsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
- Travere Therapeutics 8-K — Follow-On Equity OfferingHigh Confidence · 89%
secondary offering
Sources (1)https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/d632981d8k.htm
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
- Travere Therapeutics 8-K — Follow-On Equity OfferingHigh Confidence · 89%
secondary offering
Sources (1)https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/d632981d8k.htm
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
- Travere Therapeutics 8-K — Follow-On Equity OfferingHigh Confidence · 89%
secondary offering
Sources (1)https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/d632981d8k.htm
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Travere Therapeutics right now?
- Which regulatory precedents should Travere Therapeutics monitor in Nephrology and Drug?
- Which pipeline programs should Travere Therapeutics prioritize for competitive review?
- What signals require immediate investigation for Travere Therapeutics?
- Summarize the strategic implications of recent developments for Travere Therapeutics.
- Where is the greatest uncertainty in Travere Therapeutics's competitive positioning?